Opus Genetics, Inc. Schedule 13G/A (Amendment No. 2) reports that certain affiliated investment vehicles and related managers collectively hold 3,683,429 shares of Common Stock, representing 4.53% of the class based on 81,395,539 shares outstanding as of May 7, 2026. The filing lists the chain of control that may give shared voting and dispositive power over those shares: Bios Fund III series, Bios Equity Partners III, Bios Management, Bios Advisors, and related Cavu entities, plus named individuals Aaron G.L. Fletcher and Leslie W. Kreis. The cover pages incorporated into Item 4 provide the amount beneficially owned and percent of class; signatures show counsel/attorney-in-fact execution on May 13, 2026.
Positive
None.
Negative
None.
Insights
Affiliated funds disclose a >4% holding with layered managerial control.
The excerpt shows 3,683,429 shares (4.53%) are held in aggregate by the Bios III Funds, with shared voting/dispositive power flowing through Bios Equity III, Bios Management, and Bios Advisors. The filing explicitly ties the percentage to May 7, 2026.
Governance implications depend on whether these holders act jointly; the filing notes shared power but does not state a formal group dissolution status beyond Item 9 language. Subsequent filings will report any transactions if required.
Key Figures
Aggregated shares reported:3,683,429 sharesPercent of class:4.53%Shares outstanding used:81,395,539 shares+3 more
6 metrics
Aggregated shares reported3,683,429 sharesAggregate held by Bios III Funds and affiliates
Percent of class4.53%Based on shares outstanding as of <date>May 7, 2026</date>
Shares outstanding used81,395,539 sharesShares outstanding as of <date>May 7, 2026</date> per Form 10-Q referenced
Bios Fund III QP holding2,801,953 sharesReported as part of the Bios III Funds aggregate
Bios Fund III NT holding450,811 sharesReported as part of the Bios III Funds aggregate
Bios Fund III holding430,665 sharesReported as part of the Bios III Funds aggregate
Key Terms
Schedule 13G/A, shared voting and dispositive power, amount beneficially owned, Notice of dissolution of a group
4 terms
Schedule 13G/Aregulatory
"Amendment No. 2 ) Opus Genetics, Inc. Common Stock"
A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.
shared voting and dispositive powerregulatory
"Shared voting and dispositive power consists of 3,683,429 Shares"
What stake does Bios-affiliated group hold in Opus Genetics (IRD)?
The group holds 3,683,429 shares, representing 4.53% of common stock based on May 7, 2026. The amount is reported in the Schedule 13G/A cover pages incorporated into Item 4.
Who may exercise voting or dispositive power over those shares?
Bios Equity III, Bios Management, Bios Advisors, Cavu entities, and the named individuals Aaron G.L. Fletcher and Leslie W. Kreis are disclosed as having shared voting and dispositive power via the described ownership chain.
What is the shares outstanding figure used to calculate the percentage?
The percentage is calculated using 81,395,539 shares outstanding as of May 7, 2026, cited in the filing and referenced to the issuer’s Form 10-Q filed on May 12, 2026.
Does the filing indicate the group is dissolved or continuing?
Item 9 references that a notice of dissolution of a group may be furnished as an exhibit; the filing’s Item 9 language incorporates related persons and does not provide a dated dissolution statement in the excerpt.
Who signed the Schedule 13G/A on behalf of the reporting persons?
Signatures are by John Fucci, Attorney-in-Fact, executing on behalf of Aaron G.L. Fletcher and Leslie W. Kreis with dates shown as May 13, 2026 in the filing excerpt.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 2)
Opus Genetics, Inc.
(Name of Issuer)
Common Stock, $0.0001 par value per share
(Title of Class of Securities)
67577R102
(CUSIP Number)
05/12/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
67577R102
1
Names of Reporting Persons
AARON G.L. FLETCHER
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,683,429.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,683,429.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,683,429.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
4.53 %
12
Type of Reporting Person (See Instructions)
IN
Comment for Type of Reporting Person: Shared voting and dispositive power consists of 3,683,429 Shares held directly in the aggregate by the Bios III Funds. Bios Equity III is the general partner of each of the Bios III Funds. Bios Management is a general partner of Bios Equity III. Bios Advisors, an entity controlled by Dr. Fletcher, is the general partner of Bios Management. As the manager of Bios Advisors, Dr. Fletcher may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios III Funds. Percentage based on 81,395,539 Shares outstanding as of May 7, 2026, as reported in the Issuer's Current Report on Form 10-Q filed with the Securities and Exchange Commission on May 12, 2026.
SCHEDULE 13G
CUSIP Number(s):
67577R102
1
Names of Reporting Persons
BIOS ADVISORS GP, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
TEXAS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,683,429.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,683,429.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,683,429.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
4.53 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: Shared voting and dispositive power consists of 3,683,429 Shares held directly in the aggregate by the Bios III Funds. Bios Equity III is the general partner of each of the Bios III Funds. Bios Management is a general partner of Bios Equity III. Bios Advisors GP, LLC ("Bios Advisors") is the general partner of Bios Management and, in its capacity as such, may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios III Funds. Percentage based on 81,395,539 Shares outstanding as of May 7, 2026, as reported in the Issuer's Current Report on Form 10-Q filed with the Securities and Exchange Commission on May 12, 2026.
SCHEDULE 13G
CUSIP Number(s):
67577R102
1
Names of Reporting Persons
BIOS CAPITAL MANAGEMENT, LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
TEXAS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,683,429.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,683,429.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,683,429.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
4.53 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: Shared voting and dispositive power consists of 3,683,429 Shares held directly in the aggregate by the Bios III Funds. Bios Equity III is the general partner of each of the Bios III Funds. Bios Capital Management, LP ("Bios Management") is a general partner of Bios Equity III and, in its capacity as such, may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios III Funds. Percentage based on 81,395,539 Shares outstanding as of May 7, 2026, as reported in the Issuer's Current Report on Form 10-Q filed with the Securities and Exchange Commission on May 12, 2026.
SCHEDULE 13G
CUSIP Number(s):
67577R102
1
Names of Reporting Persons
BIOS EQUITY PARTNERS III, LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
TEXAS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,683,429.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,683,429.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,683,429.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
4.53 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: Shared voting and dispositive power consists of 3,683,429 Shares held directly in the aggregate by the Bios III Funds (defined below). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of each of Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT") (collectively, the "Bios III Funds"), and, in its capacity as such, may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios III Funds.Percentage based on 81,395,539 Shares outstanding as of May 7, 2026, as reported in the Issuer's Current Report on Form 10-Q filed with the Securities and Exchange Commission on May 12, 2026.
SCHEDULE 13G
CUSIP Number(s):
67577R102
1
Names of Reporting Persons
BIOS FUND III, LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
430,665.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
430,665.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
430,665.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.53 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: Percentage based on 81,395,539 Shares outstanding as of May 7, 2026, as reported in the Issuer's Current Report on Form 10-Q filed with the Securities and Exchange Commission on May 12, 2026.
SCHEDULE 13G
CUSIP Number(s):
67577R102
1
Names of Reporting Persons
BIOS FUND III NT, LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
450,811.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
450,811.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
450,811.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.55 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: Percentage based on 81,395,539 Shares outstanding as of May 7, 2026, as reported in the Issuer's Current Report on Form 10-Q filed with the Securities and Exchange Commission on May 12, 2026.
SCHEDULE 13G
CUSIP Number(s):
67577R102
1
Names of Reporting Persons
BIOS FUND III QP, LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
2,801,953.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
2,801,953.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,801,953.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
3.44 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: Percentage based on 81,395,539 Shares outstanding as of May 7, 2026, as reported in the Issuer's Current Report on Form 10-Q filed with the Securities and Exchange Commission on May 12, 2026.
SCHEDULE 13G
CUSIP Number(s):
67577R102
1
Names of Reporting Persons
CAVU ADVISORS, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
TEXAS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,683,429.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,683,429.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,683,429.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
4.53 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: Shared voting and dispositive power consists of 3,683,429 Shares held directly in the aggregate by the Bios III Funds. Bios Equity III is the general partner of each of the Bios III Funds. Cavu Management is a general partner of Bios Equity III. Cavu Advisors, LLC ("Cavu Advisors") is the general partner of Cavu Management and, in its capacity as such, may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios III Funds. Percentage based on 81,395,539 Shares outstanding as of May 7, 2026, as reported in the Issuer's Current Report on Form 10-Q filed with the Securities and Exchange Commission on May 12, 2026.
SCHEDULE 13G
CUSIP Number(s):
67577R102
1
Names of Reporting Persons
CAVU MANAGEMENT, LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
TEXAS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,683,429.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,683,429.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,683,429.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
4.53 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: Shared voting and dispositive power consists of 3,683,429 Shares held directly in the aggregate by the Bios III Funds. Bios Equity III is the general partner of each of the Bios III Funds. Cavu Management, LP ("Cavu Management") is a general partner of Bios Equity III and, in its capacity as such, may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios III Funds. Percentage based on 81,395,539 Shares outstanding as of May 7, 2026, as reported in the Issuer's Current Report on Form 10-Q filed with the Securities and Exchange Commission on May 12, 2026.
SCHEDULE 13G
CUSIP Number(s):
67577R102
1
Names of Reporting Persons
LESLIE W. KREIS
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,683,429.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,683,429.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,683,429.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
4.53 %
12
Type of Reporting Person (See Instructions)
IN
Comment for Type of Reporting Person: Shared voting and dispositive power consists of 3,683,429 Shares held directly in the aggregate by the Bios III Funds. Bios Equity III is the general partner of each of the Bios III Funds. Cavu Management is a general partner of Bios Equity III. Cavu Advisors, an entity controlled by Mr. Kreis, is the general partner of Cavu Management. As the manager of Cavu Advisors, Mr. Kreis may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios III Funds. Percentage based on 81,395,539 Shares outstanding as of May 7, 2026, as reported in the Issuer's Current Report on Form 10-Q filed with the Securities and Exchange Commission on May 12, 2026.
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Opus Genetics, Inc.
(b)
Address of issuer's principal executive offices:
8 DAVIS DRIVE, SUITE 220, DURHAM, NORTH CAROLINA, 27713
Item 2.
(a)
Name of person filing:
This Schedule 13G is being jointly filed by: Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Equity III, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors, Mr. Kreis, and Dr. Fletcher.
(b)
Address or principal business office or, if none, residence:
1751 River Run #400 Fort Worth, TX 76107
(c)
Citizenship:
Item 2(A) is incorporated herein by reference.
(d)
Title of class of securities:
Common Stock, $0.0001 par value per share
(e)
CUSIP No.:
67577R102
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The information contained in Item 9 of the cover pages of this Schedule 13G is hereby incorporated by reference into this Item 4.
(b)
Percent of class:
The information contained in Item 9 of the cover pages of this Schedule 13G is hereby incorporated by reference into this Item 4.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
The information contained in Item 9 of the cover pages of this Schedule 13G is hereby incorporated by reference into this Item 4.
(ii) Shared power to vote or to direct the vote:
The information contained in Item 9 of the cover pages of this Schedule 13G is hereby incorporated by reference into this Item 4.
(iii) Sole power to dispose or to direct the disposition of:
The information contained in Item 9 of the cover pages of this Schedule 13G is hereby incorporated by reference into this Item 4.
(iv) Shared power to dispose or to direct the disposition of:
The information contained in Item 9 of the cover pages of this Schedule 13G is hereby incorporated by reference into this Item 4.
Item 5.
Ownership of 5 Percent or Less of a Class.
Ownership of 5 percent or less of a class
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.
The Related Persons of this Schedule 13G are hereby incorporated by reference into this Item 9.
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
AARON G.L. FLETCHER
Signature:
/s/ John Fucci
Name/Title:
John Fucci, as Attorney-in-Fact for Aaron G.L. Fletcher
Date:
05/13/2026
BIOS ADVISORS GP, LLC
Signature:
/s/ John Fucci
Name/Title:
John Fucci/Attorney-in-Fact
Date:
05/13/2026
BIOS CAPITAL MANAGEMENT, LP
Signature:
/s/ John Fucci
Name/Title:
John Fucci/Attorney-in-Fact
Date:
05/13/2026
BIOS EQUITY PARTNERS III, LP
Signature:
/s/ John Fucci
Name/Title:
John Fucci/Attorney-in-Fact
Date:
05/13/2026
BIOS FUND III, LP
Signature:
/s/ John Fucci
Name/Title:
John Fucci/Attorney-in-Fact
Date:
05/13/2026
BIOS FUND III NT, LP
Signature:
/s/ John Fucci
Name/Title:
John Fucci/Attorney-in-Fact
Date:
05/13/2026
BIOS FUND III QP, LP
Signature:
/s/ John Fucci
Name/Title:
John Fucci/Attorney-in-Fact
Date:
05/13/2026
CAVU ADVISORS, LLC
Signature:
/s/ John Fucci
Name/Title:
John Fucci/Attorney-in-Fact
Date:
05/13/2026
CAVU MANAGEMENT, LP
Signature:
/s/ John Fucci
Name/Title:
John Fucci/Attorney-in-Fact
Date:
05/13/2026
LESLIE W. KREIS
Signature:
/s/ John Fucci
Name/Title:
John Fucci, as Attorney-in-Fact for Leslie W. Kreis, Jr.
